Pharming Group
-9%
est. 2Y upside i
Rank
#3092
Sector
Biotechnology
Est. Liquidity
~2Y
Data Quality
Data: MediumPharming Group presents a moderate upside opportunity for a job seeker.
Last updated: March 10, 2026
Successful pediatric Joenja approval (1-6 years) and positive Phase II data for other Primary Immunodeficiency Disorders drive significant market expansion, pushing revenue to $600M+ by 2027. This, combined with an expanding P/S multiple to 4.5x due to strong pipeline execution and market confidence, could justify a valuation of $2.7B, representing a 145% upside, capped at 100%.
Continued steady growth of RUCONEST and initial, albeit slower, expansion of Joenja, despite regulatory hurdles. Revenue reaches approximately $470M by 2027. The valuation multiple remains stable at 2.9x, leading to a valuation of $1.36B, or a 24% upside.
Further regulatory setbacks for Joenja, increased competition in HAE, or pipeline failures, coupled with the ongoing legal investigation, lead to revenue stagnation around $350M. The market multiple contracts to 2.0x, resulting in a valuation of $700M, a 36% downside.
Preference Stack Risk
moderateCommon shareholders are subordinate to approximately $130.9M in total debt in a liquidation scenario.
Dilution Risk
moderateAs a public company, ongoing stock-based compensation and potential future equity offerings for M&A or pipeline funding could lead to dilution.
Secondary Liquidity
activePharming Group is publicly traded on Euronext Amsterdam and NasdaqGM, providing active secondary market liquidity.
Questions to Ask at the Interview
Strategic questions based on Pharming Group's data — designed to show you've done your homework.
- 1
“Given the recent Complete Response Letter from the FDA for Joenja's expanded use, how is Pharming adjusting its regulatory strategy and clinical development plans to address the FDA's requirements, particularly for the younger pediatric population and other PID indications?”
- 2
“With the strategic decision to withdraw Ruconest from certain ex-US markets, how will the company reallocate resources to accelerate the development and commercialization of higher-growth pipeline assets like KL1333 and leniolisib for other PIDs, and what are the key milestones for these programs over the next two years?”
- 3
“As a public company, how does Pharming Group communicate and ensure that employee equity, particularly RSUs or options, retains its value and provides a meaningful return over a 2-year horizon, considering market fluctuations and potential dilution from future capital raises or stock-based compensation?”
Community
Valuation Sentiment
Our model estimates -9% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.